Tetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH) had an increase of 3.11% in short interest. TTPH’s SI was 2.83 million shares in December as released by FINRA. Its up 3.11% from 2.74 million shares previously. With 444,500 avg volume, 6 days are for Tetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH)’s short sellers to cover TTPH’s short positions. The SI to Tetraphase Pharmaceuticals Incorporated’s float is 7.68%. The stock decreased 0.51% or $0.03 during the last trading session, reaching $5.86. About 340,617 shares traded. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has risen 106.58% since December 16, 2016 and is uptrending. It has outperformed by 89.88% the S&P500.
Lmm Llc decreased Lennar Corp (LEN) stake by 1.88% reported in 2017Q2 SEC filing. Lmm Llc sold 29,625 shares as Lennar Corp (LEN)’s stock rose 12.25%. The Lmm Llc holds 1.54 million shares with $82.33M value, down from 1.57 million last quarter. Lennar Corp now has $14.36 billion valuation. The stock increased 0.43% or $0.26 during the last trading session, reaching $61.4. About 4.08 million shares traded or 17.08% up from the average. Lennar Corporation (NYSE:LEN) has risen 19.91% since December 16, 2016 and is uptrending. It has outperformed by 3.21% the S&P500.
Analysts await Lennar Corporation (NYSE:LEN) to report earnings on December, 18. They expect $1.50 EPS, up 11.94% or $0.16 from last year’s $1.34 per share. LEN’s profit will be $350.84 million for 10.23 P/E if the $1.50 EPS becomes a reality. After $1.06 actual EPS reported by Lennar Corporation for the previous quarter, Wall Street now forecasts 41.51% EPS growth.
Since October 2, 2017, it had 0 buys, and 2 insider sales for $1.90 million activity. GROSS BRUCE E had sold 15,000 shares worth $847,200. Shares for $1.06 million were sold by JAFFE JONATHAN M.
Lmm Llc increased New Media Invt Group Inc (NYSE:NEWM) stake by 157,245 shares to 439,245 valued at $5.92 million in 2017Q2. It also upped Seaspan Corp (NYSE:SSW) stake by 132,185 shares and now owns 632,185 shares. Endo Intl Plc (Call) (NASDAQ:ENDP) was raised too.
Investors sentiment decreased to 0.92 in Q2 2017. Its down 0.28, from 1.2 in 2017Q1. It turned negative, as 36 investors sold LEN shares while 139 reduced holdings. 61 funds opened positions while 149 raised stakes. 187.51 million shares or 1.47% less from 190.31 million shares in 2017Q1 were reported. Optimum Advsr reported 6,500 shares. Moreover, First Interstate Retail Bank has 0.06% invested in Lennar Corporation (NYSE:LEN). 235,717 were accumulated by Adage Prtnrs Group Ltd Co. Old Mutual Customised Solutions (Proprietary) owns 0.02% invested in Lennar Corporation (NYSE:LEN) for 2,300 shares. Cypress Asset Mngmt Tx invested in 0.05% or 4,550 shares. Hudson Valley Investment Adv has invested 0.24% in Lennar Corporation (NYSE:LEN). Nomura Asset has invested 0.02% in Lennar Corporation (NYSE:LEN). Tci Wealth stated it has 169 shares or 0% of all its holdings. Kentucky Retirement Ins Trust Fund invested in 5,565 shares. Moreover, Institute For Wealth Mgmt Ltd has 0.11% invested in Lennar Corporation (NYSE:LEN). Oakmont owns 47,656 shares. Livforsakringsbolaget Skandia Omsesidigt has invested 0.05% in Lennar Corporation (NYSE:LEN). Tower Research Cap Ltd Liability Corp (Trc) accumulated 0.01% or 1,750 shares. National Bank & Trust Of Montreal Can holds 0.01% or 155,980 shares. Huntington Fincl Bank owns 2,145 shares.
Among 24 analysts covering Lennar (NYSE:LEN), 15 have Buy rating, 0 Sell and 9 Hold. Therefore 63% are positive. Lennar had 54 analyst reports since September 22, 2015 according to SRatingsIntel. Barclays Capital downgraded the stock to “Equal-Weight” rating in Tuesday, July 11 report. As per Wednesday, June 21, the company rating was maintained by RBC Capital Markets. Wood maintained the stock with “Outperform” rating in Wednesday, March 30 report. The stock of Lennar Corporation (NYSE:LEN) earned “Outperform” rating by Raymond James on Monday, June 27. M Partners upgraded the stock to “Buy” rating in Wednesday, October 4 report. The firm has “Buy” rating by RBC Capital Markets given on Monday, October 30. Citigroup maintained Lennar Corporation (NYSE:LEN) on Wednesday, October 4 with “Neutral” rating. On Tuesday, October 31 the stock rating was maintained by KeyBanc Capital Markets with “Hold”. RBC Capital Markets maintained it with “Buy” rating and $6400 target in Thursday, July 13 report. JMP Securities upgraded Lennar Corporation (NYSE:LEN) rating on Monday, November 6. JMP Securities has “Buy” rating and $70.0 target.
Among 13 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 5 have Buy rating, 0 Sell and 8 Hold. Therefore 38% are positive. Tetraphase Pharmaceuticals had 25 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has “Market Perform” rating given on Tuesday, April 12 by BMO Capital Markets. On Wednesday, June 21 the stock rating was maintained by BMO Capital Markets with “Buy”. JMP Securities downgraded Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) on Wednesday, September 9 to “Market Perform” rating. Stifel Nicolaus maintained Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) on Monday, September 11 with “Buy” rating. The firm has “Hold” rating given on Wednesday, September 9 by Cantor Fitzgerald. On Friday, May 13 the stock rating was downgraded by Gabelli to “Neutral”. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Hold” rating by Stifel Nicolaus on Wednesday, September 9. Robert W. Baird downgraded it to “Neutral” rating and $10 target in Wednesday, September 9 report. The firm has “Hold” rating given on Friday, September 15 by Needham. The firm has “Outperform” rating by BMO Capital Markets given on Wednesday, July 26.
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $301.29 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.
Since August 17, 2017, it had 0 insider purchases, and 2 insider sales for $146,928 activity. Dumas Jacques sold $41,928 worth of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) on Thursday, August 17.
Investors sentiment increased to 2.21 in 2017 Q2. Its up 0.90, from 1.31 in 2017Q1. It is positive, as 13 investors sold Tetraphase Pharmaceuticals, Inc. shares while 19 reduced holdings. 17 funds opened positions while 25 raised stakes. 20.56 million shares or 13.43% more from 18.13 million shares in 2017Q1 were reported. Aqr Cap Limited Co invested in 21,766 shares or 0% of the stock. 401,420 are held by Morgan Stanley. Nationwide Fund Advsr has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Bancorp Of Ny Mellon holds 0% or 194,144 shares. Bnp Paribas Arbitrage Sa has 3,747 shares for 0% of their portfolio. New York State Common Retirement Fund holds 33,000 shares. Mufg Americas Hldg holds 0% or 760 shares. 28,800 were accumulated by Gsa Partners Llp. Dimensional Fund Ltd Partnership accumulated 1.10 million shares. Schwab Charles Management has 0% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Next Financial Group Inc Inc holds 0% or 227 shares in its portfolio. New York-based Tiaa Cref Inv Management Ltd Liability has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). State Board Of Administration Of Florida Retirement holds 19,923 shares. Wells Fargo And Company Mn reported 37,704 shares. Strs Ohio holds 0% or 81,000 shares in its portfolio.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.